Objective response rate of 34% (2 responses pending confirmation) and 25% (confirmed) in the 100mg daily dose expansion cohort (n=32) of ARC-20, a Phase 1/1b study of casdatifan in metastatic clear ...
Dr. Markus will oversee Arcus’s clinical development organization and portfolio that includes seven clinical-stage programs with multiple ongoing Phase 3 studies “Arcus stands out as a mid-sized ...
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases ...
Gilead Sciences and Arcus Biosciences said they’ve expanded their three-year-old collaboration. An equity stake in Arcus, board seat for Gilead’s commercial chief and a streamlined immuno-oncology ...
Precision is also using its ARCUS platform to develop a treatment to edit PCSK9, a gene that regulates the levels of low-density lipoprotein (LDL) cholesterol. In preclinical studies, and three years ...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...
Dr. Markus will oversee Arcus’s clinical development organization and portfolio that includes seven clinical-stage programs with multiple ongoing Phase 3 studies Arcus Biosciences, Inc. (NYSE:RCUS), a ...
Dr. Nuyten will oversee Arcus’s clinical development organization that includes nearly 200 employees and six clinical-stage programs targeting TIGIT, the adenosine axis (CD73 and dual A2a/A2b), HIF-2a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results